drugset
drugset / Trial / NCT07659678

CCR2 PET Imaging Head and Neck Squamous Cell Carcinoma

NCT07659678 ↗

Phase 2 Not yet recruiting 90 enrolled Washington University School of Medicine National Cancer Institute (NCI) · collab
Non-randomizedParallel-groupOpen-labelDiagnostic

Summary

This is a prospective study to evaluate the sensitivity and specificity of Cu-64 DOTA-ECL1i PET/CT imaging to serve as a novel precision imaging tool for patients with head and neck squamous cell carcinoma (HNSCC).

Timeline

Start
2026-08-31
Primary completion
2032-03-31
Completion
2032-03-31

Drugs

EvaluationDrugModalityDoseRoute
Subject 64Cu-DOTA-ECL1i Peptide — Intravenous

Indications

head and neck squamous cell carcinoma